- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01982565
Nitric Oxide Generating Gel Dressing in Patients With Diabetic Foot Ulcers (ProNOx1)
A Clinical Pilot Study of an Oxides of Nitrogen Generating Gel Dressing System to Stimulate Healing in Diabetic Foot Ulcers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a clinical study of a new wound dressing for diabetic foot ulcers (DFU). The dressing consists of 2 stable layers that when placed together release Nitric Oxide. In preclinical studies NOx delivery has caused significant vasodilation, angiogenesis and demonstrated potent anti-microbial activity.
In part 1 of the study, the dressing will be applied to up to 20 DFUs for a set period and the blood flow in and around the wound will be measured before and after application of the dressing. Any adverse events will be recorded.
If an increase in blood flow is seen and the dressing is well tolerated, part 2 will begin, which is a multi-centre, 120 patient, randomised, controlled study. 60 patients with chronic DFUs will be treated with the NOx generating dressing and 60 patients will continue to receive standard of care. The efficacy and the tolerability of the dressing will be measured.
The NOx dressing will be changed at least every 2 days and the standard of care changed as in normal clinical practice.
At weekly clinical visits the diameter, area and volume of the wound will be measured. The infective status of the wound will be assessed and the inflammatory profile of the wound will be measured.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Dundee, United Kingdom, DD1 9SY
- Ninewells Hospital
-
Edinburgh, United Kingdom, EH16 4SA
- Edinburgh Royal Infirmary
-
Glasgow, United Kingdom, G51 4TF
- Southern General Hospital
-
London, United Kingdom, SE5 9RS
- Kings College Hospital
-
Manchester, United Kingdom, M8 5RB
- Pennine Acute Hospitals Trust
-
Nottingham, United Kingdom, NG5 1PB
- Nottingham City Hospital
-
Preston, United Kingdom, PR2 9HT
- Lancashire Teaching Hospitals
-
Salford, United Kingdom, M6 8HD
- Salford Royal
-
Wakefield, United Kingdom, WF1 4DG
- Pinderfields General Hospital
-
-
West Yorkshire
-
Leeds, West Yorkshire, United Kingdom, LS9 7TF
- St James's University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients aged over 18 years.
- Diagnosed with type 1 or type 2 diabetes.
- With a chronic (present for at least 6 weeks) full-thickness foot ulcer (on or below the malleoli) not penetrating to tendon, periosteum or bone, and with a cross-sectional area between 25 and 2500 mm2.
- Patients must have pedal blood flow between normal and moderately ischaemic. Measurable as a palpable pedal pulse or in the absence of a palpable pedal pulse they must have a TcPO2 of ≥30mmHg or an ABPI of between 0.5-1.00, or > 1.2. (An ABPI of >1.2 is associated with calcification rather than ischaemia. We are including patients with an ABPI >1.2 because ABPI is measured in large arteries. NOx has the ability to dilate medium to small arterioles which are less likely to be calcified.)
- With some degree of neuropathy (as commonly seen in the Diabetes Foot Clinic).
- Able to read and understand the Volunteer Information Sheet and to provide meaningful written informed consent.
- Able and willing to follow the Protocol requirements.
Exclusion Criteria:
- Female patients who are pregnant or breast-feeding
- Any other serious disease likely to compromise the outcome of the trial
- Participation in any clinical study during the eight (8) weeks preceding the dosing period of the study
- Wound area greater than 2500 square mm;
- Patients with severe ischaemia. Measurable as absence of palpable pedal pulse and a TcPO2 of less than 30mmhg, or ABPI < 0.5 or between 1.0-1.2.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control Arm
Standard of Care
|
The clinician/podiatrist is free to use whichever treatment they would choose to use on the patient in their current clinical practice.
|
Experimental: Treatment Arm
NOx dressing applied and changed at least every 2 days for 12 weeks or until ulcer is healed.
|
The NOx dressing should be changed at least every 2 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measure the safety of the NOx generating dressing
Time Frame: Monitored at every visit until 12 weeks or ulcer is healed and at 3 month post treatment followed
|
Number of participants with adverse events during the active study period and the following 3 months post treatment
|
Monitored at every visit until 12 weeks or ulcer is healed and at 3 month post treatment followed
|
Measure the efficacy of the NOx generating dressing
Time Frame: Measured at every patient visit until healed or 12 weeks of treatment is reached
|
The time to healing of the ulcer will be measured and compared between the NOx generating dressing arm and the standard of care arm
|
Measured at every patient visit until healed or 12 weeks of treatment is reached
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measure changes in ulcer blood flow.
Time Frame: 3 months
|
In Part 1 of the study, blood flow in the ulcer will be measured by laser Doppler fluximetry before and after the NOx generating dressing is applied.
|
3 months
|
Measure changes in the inflammatory/infective status of the wounds.
Time Frame: Samples taken at every visit until 12 weeks or the ulcer is healed
|
Samples taken at every visit will be measured for microbial content and inflammatory cytokine presence and a comparison made between the 2 arms.
|
Samples taken at every visit until 12 weeks or the ulcer is healed
|
Measure the rate of repeat ulcers and breakdown in healing.
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Arthur Tucker, PhD, St Barts, London
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EDX 110
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Foot Ulcer
-
University of MinnesotaRecruitingDiabetes Mellitus | Foot Ulcer | Ulcer | Diabetic Foot Ulcer | Foot Ulcer, Diabetic | Ulcer Foot | Ulcer, Leg | Ankle UlcerUnited States
-
Community Pharmacology Services LtdKeneric HealthcareNot yet recruitingDiabetic Foot Ulcer | Diabetic Foot Ulcer Neuropathic | Diabetic Foot Ulcer Ischemic
-
University of PadovaUnknownDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Deformities FootItaly
-
Corporacion Parc TauliCompletedDiabetic Foot Ulcer | Diabetic Foot Ulcer NeuropathicPakistan
-
Johns Hopkins UniversityWithdrawnDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Mixed | Vascular Ulcer (Arterial or Venous Including Diabetic Ulcers Not Located on the Foot)
-
Baylor College of MedicineLifeNet HealthCompletedDiabetic Foot Ulcer | Deep Diabetic Foot UlcerUnited States
-
ETS Wound Care, LLCProfessional Education and Research InstituteCompletedDiabetic Foot | Diabetic Foot Ulcer | Ulcer FootUnited States
-
Exciton Technologies Inc.CompletedDiabetic Foot Ulcer | Diabetic Foot Infection | Non-healing Diabetic Foot UlcerCanada
-
National and Kapodistrian University of AthensTerminatedDiabetic Foot | Chronic Diabetic Foot Ulcer of Right Foot | Neuropathic Foot Ulcer | Chronic Diabetic Ulcer of Left Foot (Diagnosis)Greece
-
University of the PunjabHigher Education Commission (Pakistan); Centre of Excellence in Molecular Biology... and other collaboratorsRecruitingDiabetes Mellitus | Diabetic Foot | Foot Ulcer | Diabetes Complications | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Foot Ulcer Due to Type 1 Diabetes Mellitus | Foot Ulcer Due to Type 2 Diabetes Mellitus | Chronic Diabetic Ulcer of Left Foot | Chronic Diabetic Foot...Pakistan
Clinical Trials on NOx dressing
-
Edixomed LtdTerminatedNitric Oxide Generating Gel Dressing in Patients With Superficial Partial Thickness Wounds (ProNOx2)Superficial Partial Thickness Burn | Skin Graft; ComplicationsUnited Kingdom
-
TME Pharma AGProfil Institut für Stoffwechselforschung GmbHCompletedType 2 Diabetes MellitusGermany
-
TME Pharma AGCompletedType 2 Diabetes Mellitus | Systemic Lupus Erythematosus | Chronic Inflammatory Diseases
-
Chinese University of Hong KongCompleted
-
TME Pharma AGCompletedRenal ImpairmentHungary, Moldova, Republic of
-
Medinox, Inc.Orient Europharma Co., Ltd.Completed
-
TME Pharma AGCompletedType 2 Diabetes Mellitus | AlbuminuriaPoland, Germany, Romania, Hungary, Czech Republic
-
TME Pharma AGGerman Federal Ministry of Education and ResearchCompleted
-
TME Pharma AGCompletedAnemia | End Stage Renal DiseaseUnited Kingdom, Germany, Italy
-
TME Pharma AGCompletedHematopoietic Stem Cell TransplantationGermany